CD4 and lung carcinoma: A clinical study investigating PG2 plus gefitinib therapy for advanced lung cancer showed markedly higher serum CD3+, CD4+, and CD4+/CD8+ cell counts in the observation group than in the control group after treatment, accompanied by a better QOL (higher KPS scores) and fewer toxic and side effects (172).